Xeris Pharmaceuticals, a US-based drug formulation developer backed by drug producer Institut Mérieux, went public on Friday after issuing 5.7 million shares priced at $15 each, raising $85.5m.
The company’s shares opened at $19.50 on the Nasdaq Global Market on Friday. After briefly rising to $19.84 they closed at $18.80.
Xeris has developed two formulation technology platforms, XeriSol and XeriJect, that will be used to create ready-to-use injectable and infusible drugs that can be stored at room temperature.
The…
